Literature DB >> 27480665

Sarcoma: Olaratumab - really a breakthrough for soft-tissue sarcomas?

Ian Judson1, Winette T van der Graaf1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27480665     DOI: 10.1038/nrclinonc.2016.123

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger
Journal:  Lancet       Date:  2012-05-16       Impact factor: 79.321

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Authors:  Ian Judson; Jaap Verweij; Hans Gelderblom; Jörg T Hartmann; Patrick Schöffski; Jean-Yves Blay; J Martijn Kerst; Josef Sufliarsky; Jeremy Whelan; Peter Hohenberger; Anders Krarup-Hansen; Thierry Alcindor; Sandrine Marreaud; Saskia Litière; Catherine Hermans; Cyril Fisher; Pancras C W Hogendoorn; A Paolo dei Tos; Winette T A van der Graaf
Journal:  Lancet Oncol       Date:  2014-03-05       Impact factor: 41.316

4.  Clinically Relevant Molecular Subtypes in Leiomyosarcoma.

Authors:  Xiangqian Guo; Vickie Y Jo; Anne M Mills; Shirley X Zhu; Cheng-Han Lee; Inigo Espinosa; Marisa R Nucci; Sushama Varma; Erna Forgó; Trevor Hastie; Sharon Anderson; Kristen Ganjoo; Andrew H Beck; Robert B West; Christopher D Fletcher; Matt van de Rijn
Journal:  Clin Cancer Res       Date:  2015-04-20       Impact factor: 12.531

5.  Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

Authors:  Patrick Schöffski; Sant Chawla; Robert G Maki; Antoine Italiano; Hans Gelderblom; Edwin Choy; Giovanni Grignani; Veridiana Camargo; Sebastian Bauer; Sun Young Rha; Jean-Yves Blay; Peter Hohenberger; David D'Adamo; Matthew Guo; Bartosz Chmielowski; Axel Le Cesne; George D Demetri; Shreyaskumar R Patel
Journal:  Lancet       Date:  2016-02-10       Impact factor: 79.321

Review 6.  Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.

Authors:  Robert G Maki; Jean-Yves Blay; George D Demetri; Jonathan A Fletcher; Heikki Joensuu; Javier Martín-Broto; Toshirou Nishida; Peter Reichardt; Patrick Schöffski; Jonathan C Trent
Journal:  Oncologist       Date:  2015-06-12

7.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Authors:  William D Tap; Robin L Jones; Brian A Van Tine; Bartosz Chmielowski; Anthony D Elias; Douglas Adkins; Mark Agulnik; Matthew M Cooney; Michael B Livingston; Gregory Pennock; Meera R Hameed; Gaurav D Shah; Amy Qin; Ashwin Shahir; Damien M Cronier; Robert Ilaria; Ilaria Conti; Jan Cosaert; Gary K Schwartz
Journal:  Lancet       Date:  2016-06-09       Impact factor: 79.321

  7 in total
  1 in total

1.  Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?

Authors:  Anastasios Kyriazoglou; Flora Zagouri; Meletios A Dimopoulos
Journal:  ESMO Open       Date:  2019-06-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.